Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 3;12(1):e12006.
doi: 10.1002/pul2.12006. eCollection 2022 Jan.

Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease

Affiliations

Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease

Daniel P Cook et al. Pulm Circ. .

Abstract

Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD). Little is known about the prevalence and clinical profiles of patients with COPD-PH. We report the clinical characteristics, hemodynamic profiles, and prognosis in a large population of patients with COPD referred for right heart catheterization (RHC). We extracted data from all patients referred for RHC between 1997 and 2017 in Vanderbilt's deidentified medical record. PH was defined as mean pulmonary artery pressure >20 mmHg. Pre- and postcapillary PH were defined according to contemporary guidelines. COPD was identified using a validated rules-based algorithm requiring international classification of diseases codes relevant to COPD. We identified 6065 patients referred for RHC, of whom 1509 (24.9%) had COPD and 1213 had COPD and PH. Patients with COPD-PH had a higher prevalence of diabetes, atrial fibrillation, and heart failure compared with COPD without PH. Approximately 55% of patients with COPD-PH had elevated left ventricle (LV) filling pressure. Pulmonary function testing data from individuals with COPD-PH revealed subtype differences, with precapillary COPD-PH having lower diffusion capacity of the lungs for carbon monoxide (DLCO) values than the other COPD-PH subtypes. Patients with COPD-PH had significantly increased mortality compared with COPD alone (hazard ratio [HR]: 1.70, 95% confidence interval [CI]: 1.28-2.26) with the highest mortality among the combined pre- and postcapillary COPD-PH subgroup (HR: 2.39; 95% CI: 1.64-3.47). PH is common among patients with COPD referred for RHC. The etiology of PH in patients with COPD is often mixed due to multimorbidity and is associated with high mortality, which may have implications for risk factor management.

Keywords: COPD; hemodynamic phenotyping; survival outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Flow diagram for patient categorization. RHC, right heart catheterization; COPD, chronic obstructive pulmonary disease; PH, pulmonary hypertension; Cpc‐PH, combined postcapillary and precapillary pulmonary hypertension; Ipc‐PH, isolated postcapillary pulmonary hypertension; mPAP, mean pulmonary arterial pressure; Pc‐PH, precapillary pulmonary hypertension; U‐PH, undefined pulmonary hypertension; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance
Figure 2
Figure 2
Forest plot of adjusted hazard ratio for mortality in COPD‐PH compared to COPD without PH. Mortality adjusted for the following variables determined within 6 months of right heart catheterization: age, sex, race. HR, hazard ratio; 95% CI, confidence interval. Cpc‐PH, combined postcapillary and precapillary pulmonary hypertension; Ipc‐PH, isolated postcapillary pulmonary hypertension; Pc‐PH, precapillary pulmonary hypertension; U‐PH, undefined pulmonary hypertension

References

    1. Awerbach JD, Stackhouse KA, Lee J, Dahhan T, Parikh KS, Krasuski RA. Outcomes of lung disease‐associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. Respir Med. 2019;150:126–30. 10.1016/j.rmed.2019.03.004 - DOI - PubMed
    1. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, Hill C, Hamilton N, Armstrong IJ, Billings C, Pollard L, Wild JM, Lawrie A, Lawson R, Sabroe I, Kiely DG. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41:1292–301. 10.1183/09031936.00079512 - DOI - PubMed
    1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. 10.1183/13993003.01913-2018 - DOI - PMC - PubMed
    1. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36:752–8. 10.1136/thx.36.10.752 - DOI - PMC - PubMed
    1. Oswald‐Mammosser M, Apprill M, Bachez P, Ehrhart M, Weitzenblum E. Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type. Respiration. 1991;58:304–10. 10.1159/000195950 - DOI - PubMed